Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India · Delayed Price · Currency is INR | Market Cap | 14.33B +0.9% |
| Revenue (ttm) | 3.16B +11.7% |
| Net Income | 451.90M -27.0% |
| EPS | 6.67 -27.4% |
| Shares Out | 66.06M |
| PE Ratio | 32.54 |
| Forward PE | n/a |
| Dividend | 2.50 (1.15%) |
| Ex-Dividend Date | Sep 4, 2026 |
| Volume | 41,713 |
| Open | 216.27 |
| Previous Close | 216.25 |
| Day's Range | 215.00 - 218.90 |
| 52-Week Range | 155.00 - 264.50 |
| Beta | -0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India. [Read more]
Financial Performance
In fiscal year 2026, Jagsonpal Pharmaceuticals's revenue was 2.87 billion, an increase of 6.89% compared to the previous year's 2.69 billion. Earnings were 430.82 million, a decrease of -22.18%.
Financial StatementsNews
Jagsonpal Pharmaceuticals Transcript: Q2 26/27
Q2 consolidated revenue rose 29% YoY to INR 96 crore, while H1 EBITDA margin reached 22.9%. Management targets Q3 revenue above INR 100 crore and INR 500 crore by 2028, driven organically, with acquisitions broadening channels and therapy reach.
Jagsonpal Pharmaceuticals Quarterly report: Q2 2027
Jagsonpal Pharmaceuticals has published its Q2 2027 quarterly earnings report on October 29, 2026.
Jagsonpal Pharmaceuticals Slides: Q2 2027
Jagsonpal Pharmaceuticals has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 29, 2026.
Jagsonpal Pharmaceuticals Slides: Investor presentation
Jagsonpal Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Jagsonpal Pharmaceuticals Transcript: Q1 26/27
Q1 FY27 saw 9% revenue growth, 21% EBITDA growth, and 22% PAT growth, with strong margin expansion and a successful Aequitas acquisition. The company outpaced industry growth, executed a major share buyback, and targets continued outperformance and integration synergies.
Jagsonpal Pharmaceuticals Quarterly report: Q1 2027
Jagsonpal Pharmaceuticals has published its Q1 2027 quarterly earnings report on July 30, 2026.
Jagsonpal Pharmaceuticals Slides: Q1 2027
Jagsonpal Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Jagsonpal Pharmaceuticals completes 77.21% acquisition of Aequitas Healthcare
Jagsonpal Pharmaceuticals has announced the completion of its acquisition of a 77.21% equity stake in Aequitas Healthcare Private Limited. This acquisition is part of a proposed plan to acquire an…
Jagsonpal Pharmaceuticals completes 69.77% stake acquisition in Aequitas Healthcare
Jagsonpal Pharmaceuticals Limited has successfully completed the acquisition of a 69.77% equity stake in Aequitas Healthcare Private Limited, according to a recent filing with the National Stock Excha...
Jagsonpal Pharmaceuticals surges over 7% after announcing Rs 20.8 crore deal to acquire Aequitas Healthcare
Jagsonpal Pharmaceuticals traded at Rs 248.05 on the NSE in early dealings on June 30, up 7.67 percent or Rs 17.67 over its previous close of Rs 230.38, ranking among…
Jagsonpal Pharmaceuticals Transcript: Q4 25/26
Q4 FY 2026 delivered a strong turnaround with 10% revenue growth and 31% PAT growth year-on-year, outpacing the pharma industry. Management reaffirmed 12%-15% growth guidance, supported by robust cash returns to shareholders and continued focus on MR productivity and brand strength.
Jagsonpal Pharmaceuticals Quarterly report: Q4 2026
Jagsonpal Pharmaceuticals has published its Q4 2026 quarterly earnings report on April 27, 2026.
Jagsonpal Pharmaceuticals Slides: Q4 2026
Jagsonpal Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 27, 2026.
Jagsonpal Pharmaceuticals Annual report: Q4 2026
Jagsonpal Pharmaceuticals has published its Q4 2026 annual report on April 27, 2026.
Jagsonpal Pharmaceuticals Transcript: Q3 25/26
Q3 results were flat due to market and internal transitions, but nine-month performance showed 6% revenue and 13% bottom-line growth. Management expects double-digit growth from Q4, driven by price, new products, and volume, with strong cash generation and disciplined capital allocation.
Jagsonpal Pharmaceuticals Quarterly report: Q3 2026
Jagsonpal Pharmaceuticals has published its Q3 2026 quarterly earnings report on January 22, 2026.
Jagsonpal Pharmaceuticals Slides: Q3 2026
Jagsonpal Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 22, 2026.
Jagsonpal Pharmaceuticals shares decline nearly 3% today as revenue and EBITDA soften in Q2
Shares of Jagsonpal Pharmaceuticals traded lower on Tuesday, November 4, falling 2.86% to Rs 220 in morning trade, after the...
Jagsonpal Pharmaceuticals shares drop 2.6% after USFDA issues warning letter for manufacturing lapses at API plant
Jagsonpal Pharmaceuticals shares fell over 2% after the US Food and Drug Administration (USFDA) issued a warning letter citing significant manufacturing lapses at its Rajasthan-based active pharmaceut...
Jagsonpal Pharmaceuticals acquires Resilient Cosmeceuticals’ India business for Rs 24 crore
Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) has announced the acquisition of Resilient Cosmeceuticals Private Limited’s India business for ₹24 crore. The deal, funded through inte...
Jagsonpal Pharmaceuticals shares jump nearly 6% on strong Q3 FY25 results
Jagsonpal Pharmaceuticals Limited shares surged nearly 6% on January 23, 2025, following the announcement of its robust Q3 FY25 financial performance. The stock traded at ₹241, up by ₹12.75, reflectin...